Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.

Blood - 14 May 2009

Pérez-Andreu Virginia, Roldán Vanessa, Antón Ana Isabel, García-Barberá Nuria, Corral Javier, Vicente Vicente, González-Conejero Rocio

Abstract excerpt

VKORC1 and CYP2C9 polymorphisms are used to predict the safe dose of oral anticoagulant therapy. A new variant of CYP4F2 (V433M) has recently been related to the required warfarin dose. We evaluated its influence in earliest response to acenocoumarol in 100 selected men who started anticoagulation (3 mg for 3 consecutive days). V433M genotype exerted a gene dosage-dependent effect on the decrease of factors II,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation Tests

Share to Cytochrome P450 Family 4

Share to Drug Dosage Calculations

Share to Methionine

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 19270263
DOI: 10.1182/blood-2008-09-176222

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.PMID 19270263Read ↗

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.Semantic proximity Read ↗

The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.Semantic proximity Read ↗

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.Semantic proximity Read ↗

Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.Semantic proximity Read ↗

Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.Semantic proximity Read ↗

Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.Semantic proximity Read ↗

P-glycoprotein: a clue to vitamin K antagonist stabilization.Semantic proximity Read ↗

The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.